相关临床试验
12
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1829
已完成
11
91.7%
招募中
1
8.3%
暂无批准数据
- Researchers from the University of Reading and Technical University of Denmark demonstrated that mRNA technology can protect muscle tissue from snake venom-induced damage for the first time. - The treatment uses mRNA wrapped in lipid nanoparticles to teach cells to produce protective antibodies, reducing muscle damage from Bothrops asper venom within 12-24 hours. - Laboratory tests showed the approach reduced key muscle damage markers like creatine kinase and lactate dehydrogenase while preserving healthy muscle structure. - The technology could address a critical gap in snakebite treatment, as current antivenoms struggle to reach damaged muscle tissue around bite sites.
- Scientists have developed a revolutionary nanobody-based antivenom that effectively neutralizes venoms from 17 dangerous African elapid species, including cobras, mambas, and rinkhals. - The recombinant antivenom combines eight engineered nanobodies that target seven key toxin families, outperforming traditional horse-antibody-based treatments in preventing both death and tissue damage. - This breakthrough offers potential for safer, more scalable snakebite treatment that could be manufactured independently of animals, addressing a neglected tropical disease affecting over 300,000 people annually in Africa. - While promising, challenges remain regarding human dosing requirements and production costs that may impact accessibility in resource-limited regions where snakebites are most prevalent.
